Levetiracetam Accord (Levetiracetam)

Levetiracetam binds to the synaptic vesicle protein SV2A, which modulates neurotransmitter release. This action stabilises neuronal membranes, reduces excitatory neurotransmission, and lowers neuronal hyper‑excitability, thereby preventing the spread of seizure activity in the brain.

The appropriate dose of Levetiracetam Accord is determined by the prescribing clinician based on the patient’s age, weight, renal function, seizure type, and response to therapy. No fixed dosing regimen is provided here; the prescriber tailors the regimen to each individual.

Levetiracetam is classified with an unknown pregnancy category, meaning the risk cannot be definitively established. It should only be used during pregnancy or lactation if the potential benefits outweigh possible risks, and the decision should be made in consultation with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any temperature‑controlled requirements) and the necessary import documentation.

Levetiracetam has a unique mechanism targeting SV2A, which differs from many traditional antiepileptics that act on sodium channels or GABA receptors. It is generally well tolerated, has few drug‑enzyme interactions, and can be used as monotherapy or adjunct therapy, offering an alternative when other agents are ineffective or poorly tolerated.

Levetiracetam Accord should be stored at room temperature, below 25 °C. Keep the tablets in their original container, protect them from moisture and direct sunlight, and ensure the packaging remains sealed until use to maintain product stability.

Levetiracetam Accord is taken orally, usually as a tablet. It may be swallowed whole with water and can be taken with or without food. The exact timing and frequency are determined by the prescribing physician based on the individual treatment plan.

Serious risks include severe allergic reactions such as anaphylaxis, rare skin conditions like Stevens‑Johnson syndrome or toxic epidermal necrolysis, and neuropsychiatric events such as suicidal thoughts or marked mood changes. Patients should be monitored closely for any of these signs and seek immediate medical attention if they occur.

Levetiracetam Accord should be avoided in patients with known hypersensitivity to levetiracetam or any of its excipients. Caution is also advised for individuals with severe renal impairment unless dose adjustments are made, and it is not recommended for use in pregnancy or breastfeeding without a clear medical justification.